Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990) Stock Forecast & Price Target

Compare

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

6990 Analyst Ratings

Moderate Buy

2 Buy

0 Hold

0 Sell

Based on 2 analysts giving stock ratings to

Sichuan

Kelun-Biotech Biopharmaceutical Co., Ltd. Class H

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

6990 Stock 12 Month Forecast

Average Price Target

HK$547.50

▲(55.81% Upside)

Based on 2 Wall Street analysts offering 12 month price targets for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H in the last 3 months. The average price target is HK$547.50 with a high forecast of HK$550.00 and a low forecast of HK$545.00. The average price target represents a 55.81% change from the last price of HK$351.40.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"158":"HK$158","551":"HK$551","256.25":"HK$256.3","354.5":"HK$354.5","452.75":"HK$452.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":550,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$550.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":547.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$547.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":545,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$545.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[158,256.25,354.5,452.75,551],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,401.2,412.6461538461538,424.09230769230766,435.53846153846155,446.9846153846154,458.4307692307692,469.87692307692305,481.3230769230769,492.7692307692308,504.2153846153846,515.6615384615385,527.1076923076923,538.5538461538462,{"y":550,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,401.2,412.45384615384614,423.7076923076923,434.96153846153845,446.2153846153846,457.46923076923076,468.7230769230769,479.9769230769231,491.2307692307692,502.4846153846154,513.7384615384615,524.9923076923077,536.2461538461539,{"y":547.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,401.2,412.26153846153846,423.32307692307694,434.38461538461536,445.44615384615383,456.5076923076923,467.5692307692308,478.63076923076926,489.6923076923077,500.75384615384615,511.81538461538463,522.876923076923,533.9384615384615,{"y":545,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":183.9,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":177,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":163.3,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":159.3,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":231,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":332.8,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":327.2,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":405.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":486,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":514,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":448,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":440,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":401.2,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetHK$550.00

Average Price TargetHK$547.50

Lowest Price TargetHK$545.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Unknown Analyst

CICC

Not Ranked

CICC

HK$550

Buy

56.52%

Upside

Reiterated

02/10/26

CICC Reaffirms Their Buy Rating on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990)

Rebecca Liang

Bernstein

HK$545

Buy

55.09%

Upside

Reiterated

02/09/26

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990) Receives a Buy from Bernstein

Unknown Analyst

UBS

Not Ranked

UBS

HK$519→HK$593

Buy

68.75%

Upside

Reiterated

12/04/25

Yang Huang

J.P. Morgan

HK$545

Buy

55.09%

Upside

Reiterated

11/24/25

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990) Receives a Buy from J.P. Morgan

Unknown Analyst

HSBC

Not Ranked

HSBC

HK$549

Buy

56.23%

Upside

Reiterated

10/23/25

Unknown Analyst

BOCOM International Holdings Company

Not Ranked

BOCOM International Holdings Company

HK$507→HK$549

Buy

56.23%

Upside

Reiterated

10/22/25

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990) Receives a Buy from BOCOM International Holdings Company

Unknown Analyst

Bank of America Securities

Not Ranked

Bank of America Securities

HK$522

Hold

48.55%

Upside

Reiterated

10/21/25

Bank of America Securities Remains a Hold on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990)

Unknown Analyst

Huatai Securities

Not Ranked

Huatai Securities

HK$559.38

Buy

59.19%

Upside

Reiterated

10/20/25

Huatai Securities Sticks to Their Buy Rating for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990)

Matthew Yan

CLSA

HK$548.6

Buy

56.12%

Upside

Reiterated

10/19/25

CLSA Keeps Their Buy Rating on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990)

Unknown Analyst

Guotai Haitong

Not Ranked

Guotai Haitong

HK$519.2

Buy

47.75%

Upside

Reiterated

08/26/25

Jill Wu

CMB International Securities

HK$498.55

Buy

41.88%

Upside

Reiterated

08/21/25

Jialin Zhang

Nomura

HK$211.87→HK$434.36

Hold

23.61%

Upside

Downgraded

08/20/25

Nomura downgrades Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990) to a Hold

Wangbin Zhou

Citi

HK$330→HK$560

Buy

59.36%

Upside

Reiterated

08/20/25

Citi Keeps Their Buy Rating on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990)

Cui Cui

Jefferies

HK$300→HK$520

Buy

47.98%

Upside

Reiterated

08/19/25

Jefferies Reaffirms Their Buy Rating on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990)

Ziyi Chen

Goldman Sachs

HK$406.74→HK$454.04

Buy

29.21%

Upside

Reiterated

08/19/25

Goldman Sachs Sticks to Its Buy Rating for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Unknown Analyst

CICC

Not Ranked

CICC

HK$550

Buy

56.52%

Upside

Reiterated

02/10/26

CICC Reaffirms Their Buy Rating on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990)

Rebecca Liang

Bernstein

HK$545

Buy

55.09%

Upside

Reiterated

02/09/26

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990) Receives a Buy from Bernstein

Unknown Analyst

UBS

Not Ranked

UBS

HK$519→HK$593

Buy

68.75%

Upside

Reiterated

12/04/25

Yang Huang

J.P. Morgan

HK$545

Buy

55.09%

Upside

Reiterated

11/24/25

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990) Receives a Buy from J.P. Morgan

Unknown Analyst

HSBC

Not Ranked

HSBC

HK$549

Buy

56.23%

Upside

Reiterated

10/23/25

Unknown Analyst

BOCOM International Holdings Company

Not Ranked

BOCOM International Holdings Company

HK$507→HK$549

Buy

56.23%

Upside

Reiterated

10/22/25

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990) Receives a Buy from BOCOM International Holdings Company

Unknown Analyst

Bank of America Securities

Not Ranked

Bank of America Securities

HK$522

Hold

48.55%

Upside

Reiterated

10/21/25

Bank of America Securities Remains a Hold on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990)

Unknown Analyst

Huatai Securities

Not Ranked

Huatai Securities

HK$559.38

Buy

59.19%

Upside

Reiterated

10/20/25

Huatai Securities Sticks to Their Buy Rating for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990)

Matthew Yan

CLSA

HK$548.6

Buy

56.12%

Upside

Reiterated

10/19/25

CLSA Keeps Their Buy Rating on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990)

Unknown Analyst

Guotai Haitong

Not Ranked

Guotai Haitong

HK$519.2

Buy

47.75%

Upside

Reiterated

08/26/25

Jill Wu

CMB International Securities

HK$498.55

Buy

41.88%

Upside

Reiterated

08/21/25

Jialin Zhang

Nomura

HK$211.87→HK$434.36

Hold

23.61%

Upside

Downgraded

08/20/25

Nomura downgrades Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990) to a Hold

Wangbin Zhou

Citi

HK$330→HK$560

Buy

59.36%

Upside

Reiterated

08/20/25

Citi Keeps Their Buy Rating on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990)

Cui Cui

Jefferies

HK$300→HK$520

Buy

47.98%

Upside

Reiterated

08/19/25

Jefferies Reaffirms Their Buy Rating on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990)

Ziyi Chen

Goldman Sachs

HK$406.74→HK$454.04

Buy

29.21%

Upside

Reiterated

08/19/25

Goldman Sachs Sticks to Its Buy Rating for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H

3 Months

xxx

Success Rate

3/4 ratings generated profit

Average Return

+15.43%

reiterated a xxx

rating 7 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +15.43% per trade.

1 Year

Jill WuCMB International Securities

Success Rate

5/6 ratings generated profit

Average Return

+93.72%

reiterated a buy rating 7 months ago

Copying Jill Wu's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +93.72% per trade.

2 Years

xxx

Success Rate

5/6 ratings generated profit

Average Return

+86.12%

reiterated a xxx

rating 7 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 83.33% of your transactions generating a profit, with an average return of +86.12% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

6990 Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 6990 has received 6 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 6990 average Analyst price target in the past 3 months is 547.50.

Each month's total comprises the sum of three months' worth of ratings.

6990 Financial Forecast

6990 Earnings Forecast

Next quarter’s earnings estimate for 6990 is -HK$1.51 with a range of -HK$1.51 to -HK$1.51. The previous quarter’s EPS was -HK$0.73. 6990 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year 6990 has Performed in-line its overall industry.

6990 Sales Forecast

Next quarter’s sales forecast for 6990 is HK$1.16B with a range of HK$948.69M to HK$1.38B. The previous quarter’s sales results were HK$1.02B. 6990 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year 6990 has Performed in-line its overall industry.

6990 Stock Forecast FAQ

What is HK:6990’s average 12-month price target, according to analysts?

Based on analyst ratings, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s 12-month average price target is 547.50.

What is HK:6990’s upside potential, based on the analysts’ average price target?

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H has 55.81% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H a Buy, Sell or Hold?

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.

What is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s share price target?

The average share price target for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H is 547.50. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is HK$550.00 ,and the lowest forecast is HK$545.00. The average share price target represents 55.81% Increase from the current price of HK$351.4.

What do analysts say about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H?

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.

How can I buy shares of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H?

To buy shares of HK:6990, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990) Stock Forecast & Price Target

6990 Analyst Ratings

6990 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H

6990 Analyst Recommendation Trends

6990 Financial Forecast

6990 Earnings Forecast

6990 Sales Forecast

6990 Stock Forecast FAQ

Detailed List of Analyst Forecasts